Medix Biochemica is launching a rejuvenated brand to reflect both the exciting improvements to its offering as a result of recent acquisitions, and its ongoing commitment to the in vitro diagnostics (IVD) industry.

Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH, a German manufacturer of innovative and high-quality raw materials in molecular diagnostics.

This year marks the fifth anniversary of Medix Biochemica in China. Over the past five years, Medix Biochemica China, and China’s IVD industry have undergone significant changes and developments.

Medix Biochemica presented the findings of a study ‘Monoclonal Serum Amyloid A antibodies applicable to human and veterinary diagnostic immunoassays with wide detection ranges’ in 2021 AACC exhibition in Atlanta, on September 28th.

Medix Biochemica has acquired 100 percent of the shares of Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology, and immunology.

We are pleased to announce a further expansion of our portfolio with the introduction of several new products for the development of diagnostic assays: